RT Journal Article
SR Electronic
T1 Predicting the impact of disruptions in lymphatic filariasis elimination programmes due to the outbreak of coronavirus disease (COVID-19) and possible mitigation strategies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.06.20227017
DO 10.1101/2020.11.06.20227017
A1 Prada, Joaquín M.
A1 Stolk, Wilma A.
A1 Davis, Emma L.
A1 Touloupou, Panayiota
A1 Sharma, Swarnali
A1 Muñoz, Johanna
A1 Caja Rivera, Rocio M.
A1 Reimer, Lisa J.
A1 Michael, Edwin
A1 de Vlas, Sake J
A1 Hollingsworth, T Déirdre
YR 2020
UL http://medrxiv.org/content/early/2020/11/07/2020.11.06.20227017.abstract
AB Background In view of the current global COVID-19 pandemic, mass drug administration interventions for neglected tropical diseases, including lymphatic filariasis, have been halted. We used mathematical modelling to estimate the impact of delaying or cancelling treatment rounds and explore possible mitigation strategies.Methods We used three established lymphatic filariasis transmission models to simulate infection trends in settings with annual treatment rounds and programme delays in 2020 of 6, 12, 18 or 24 months. We then evaluated the impact of various mitigation strategies upon resuming activities.Results The delay in achieving the elimination goals is on average similar to the number of years the treatment rounds are missed. Enhanced interventions implemented for as little as one year can allow catch-up on the progress lost, and if maintained throughout the programme can lead to acceleration of up to 3 years.Conclusions In general, a short delay in the programme does not cause major delay in achieving the goals. Impact is strongest in high endemicity areas. Mitigation strategies such as biannual treatment or increased coverage are key to minimizing the impact of the disruption once the programme resumes; and lead to potential acceleration, should these enhanced strategies be maintained.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Bill and Melinda Gates Foundation through the NTD Modelling Consortium (grant number OPP1184344).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No unpublished data was collected or used for this study. Thus IRB approval was not needed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo unpublished data was collected or used for this study. All additional information available in the supplementary materials